BRPI0410875A - método de inibição do crescimento de tumor com anticorpos de fator antitecido - Google Patents
método de inibição do crescimento de tumor com anticorpos de fator antitecidoInfo
- Publication number
- BRPI0410875A BRPI0410875A BRPI0410875-2A BRPI0410875A BRPI0410875A BR PI0410875 A BRPI0410875 A BR PI0410875A BR PI0410875 A BRPI0410875 A BR PI0410875A BR PI0410875 A BRPI0410875 A BR PI0410875A
- Authority
- BR
- Brazil
- Prior art keywords
- growth inhibition
- inhibition method
- factor growth
- tumor factor
- tumor growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
"MéTODO DE INIBIçãO DO CRESCIMENTO DE TUMOR COM ANTICORPOS DE FATOR ANTITECIDO". A presente invenção refere-se a um método de uso dos antagonistas de fator de tecido para tratar doenças proliferativas, caracterizado pela neovascularização tal como câncer, artrite reumatóide, psoríase, ou retinopatia proliferativa, ou degeneração macular. Os antagonistas de fator de tecido, capazes de prevenção rápida da coagulação sangüínea através das trilhas extrínsecas são também capazes de inibir o crescimento de tumor nos mamíferos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47517403P | 2003-05-30 | 2003-05-30 | |
PCT/US2004/016663 WO2004110363A2 (en) | 2003-05-30 | 2004-05-27 | Method of inhibiting tumor growth with anti-tissue factor antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0410875A true BRPI0410875A (pt) | 2006-07-04 |
Family
ID=33551529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0410875-2A BRPI0410875A (pt) | 2003-05-30 | 2004-05-27 | método de inibição do crescimento de tumor com anticorpos de fator antitecido |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050031615A1 (pt) |
EP (1) | EP1633309A4 (pt) |
JP (1) | JP2006526641A (pt) |
KR (1) | KR20060035608A (pt) |
CN (1) | CN100528229C (pt) |
BR (1) | BRPI0410875A (pt) |
CA (1) | CA2527621A1 (pt) |
NO (1) | NO20056216L (pt) |
WO (1) | WO2004110363A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
CN101115494A (zh) * | 2004-04-16 | 2008-01-30 | 斯克里普斯研究学院 | 调节血管形成的方法 |
JP2009508476A (ja) * | 2005-08-31 | 2009-03-05 | セントカー・インコーポレーテツド | 高められたエフェクター機能をもつ抗体定常領域の製造用の宿主細胞株 |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
JP5808254B2 (ja) | 2009-02-20 | 2015-11-10 | ガニメド ファーマシューティカルズ アーゲー | 癌の診断および治療のための方法および組成物 |
CN111012921A (zh) | 2010-06-15 | 2020-04-17 | 根马布股份公司 | 针对组织因子的人抗体药物缀合物 |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
MX341147B (es) | 2011-05-13 | 2016-08-09 | Ganymed Pharmaceuticals Ag | Anticuerpos para el tratamiento del cáncer que expresa cldn6. |
CN104056267A (zh) * | 2013-03-18 | 2014-09-24 | 苏州纳诺康生物技术有限公司 | 用组织因子抗体提高乳腺癌内分泌药物治疗效果的方法 |
WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5589173A (en) * | 1986-11-04 | 1996-12-31 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
US6036955A (en) * | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
AU5093593A (en) * | 1992-08-28 | 1994-03-29 | Scripps Research Institute, The | Inhibition of tumor metastasis via neutralization of tissue factor function |
US5726147A (en) * | 1993-06-01 | 1998-03-10 | The Scripps Research Institute | Human mutant tissue factor compositions useful as tissue factor antagonists |
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
EP0833911B1 (en) * | 1995-06-07 | 2004-05-12 | Ortho Pharmaceutical Corporation | Cdr-grafted anti-tissue factor antibodies and methods of use thereof |
US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
US6677436B1 (en) * | 1998-04-03 | 2004-01-13 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody |
EP1263960A2 (en) * | 2000-03-16 | 2002-12-11 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
US6703494B2 (en) * | 2000-03-16 | 2004-03-09 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
KR20040045478A (ko) * | 2001-10-02 | 2004-06-01 | 노보 노르디스크 에이/에스 | 인간 조직인자 항체 |
TWI338009B (en) * | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
AU2003277832A1 (en) * | 2002-10-31 | 2004-05-25 | Novo Nordisk A/S | Humanized tissue factor antibodies |
US7425328B2 (en) * | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
-
2004
- 2004-05-27 CN CNB2004800214931A patent/CN100528229C/zh not_active Expired - Fee Related
- 2004-05-27 EP EP04776131A patent/EP1633309A4/en not_active Withdrawn
- 2004-05-27 JP JP2006514980A patent/JP2006526641A/ja not_active Ceased
- 2004-05-27 US US10/855,664 patent/US20050031615A1/en not_active Abandoned
- 2004-05-27 CA CA002527621A patent/CA2527621A1/en not_active Abandoned
- 2004-05-27 KR KR1020057022981A patent/KR20060035608A/ko not_active Application Discontinuation
- 2004-05-27 WO PCT/US2004/016663 patent/WO2004110363A2/en active Application Filing
- 2004-05-27 BR BRPI0410875-2A patent/BRPI0410875A/pt not_active Application Discontinuation
-
2005
- 2005-12-29 NO NO20056216A patent/NO20056216L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1633309A4 (en) | 2007-06-13 |
CN100528229C (zh) | 2009-08-19 |
WO2004110363A2 (en) | 2004-12-23 |
US20050031615A1 (en) | 2005-02-10 |
NO20056216L (no) | 2006-02-24 |
CA2527621A1 (en) | 2004-12-23 |
CN1829531A (zh) | 2006-09-06 |
JP2006526641A (ja) | 2006-11-24 |
EP1633309A2 (en) | 2006-03-15 |
WO2004110363A3 (en) | 2006-05-11 |
KR20060035608A (ko) | 2006-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0112038A (pt) | Triazolopirimidinas substituìdas como agentes anticâncer | |
BR112012031727A2 (pt) | conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença. | |
DE60331537D1 (de) | Kombinationen zur behandlung von multiplem myelom | |
BRPI0608175A2 (pt) | método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides | |
NO20055209D0 (no) | Peptabody for cancerbehandling | |
WO2004113571A3 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis | |
BR112019023758A2 (pt) | vírus da doença newcastle e seus usos | |
WO2006020722A3 (en) | Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting | |
NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
NO20056216L (no) | Fremgangmate for inhibering av tumor vekst med anti-vevsfaktor antistoffer | |
EA201070929A1 (ru) | ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ | |
BRPI0406834A (pt) | Tratamento de doença com agonistas totais do receptor nach alfa-7 | |
DK1017675T3 (da) | Stærkt lipofile camptothecinderivater | |
WO2006014999A3 (en) | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease | |
DE60215682D1 (de) | AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ | |
EA200970387A1 (ru) | Соль п-толуолсульфокислоты 5-амино-3-(2`-о-ацетил-3`-дезокси-бета-d-рибофуранозил)-3н-тиазоло[4,5-d]пиримидин-2-она и способы получения | |
PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
DE502004008819D1 (de) | Medikament zur wachstumsinhibierung von tumoren | |
DE602004016950D1 (de) | Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung | |
BR0309226A (pt) | Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável | |
BRPI0414700A (pt) | 6-[(substituìdo)fenil]triazolopirimidinas como agentes anti-cáncer | |
HK1074840A1 (en) | Novel dithiolopyrrolones with therapeutic activity | |
ATE480552T1 (de) | Stq-peptide | |
BR112022001814A2 (pt) | Métodos de tratamento de câncer multifocal | |
ATE406375T1 (de) | Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |